

REC Ref No.	IRAS No.	Name of Trial	Target Number of Participants Available?	Recruitment Target	Target Date To Recruit Participants Available?	Date Agreed To Recruit Target Number of Participants	Recruitment Total	Date Study Closed to Recruitment	Recruitment Closure Reason	RTT Met?
19/WS/0107	256189	A pivotal study of derazantinib in patients with inoperable or advanced intrahepatic cholangiocarcinoma and FGFR2 gene fusions or FGFR2 gene mutations or amplifications	Number Agreed	2	Date Agreed	31/12/2021	0	31/12/2021	Recruitment Finished	No
20/NW/0383	287807	A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734TM) Treatment of COVID-19 in an Outpatient Setting	Number Agreed	12	Date Agreed	30/06/2021	0	30/06/2021	Withdrawn By Sponsor	No
20/SC/0111	276734	A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma	Number Agreed	2	Date Agreed	31/05/2021	2	01/07/2021	Recruitment Finished	Yes
20/LO/1278	288502	A multicenter, Phase 2a, open-label, non-randomized study evaluating the efficacy, safety, and tolerability of BIVV020 in adults with persistent/chronic immune thrombocytopenia (ITP)-PDY16894	Number Agreed	1	Date Agreed	30/07/2021	0	30/07/2021	Recruitment Finished	No
20/EE/0170	1003070	Multicenter, randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction	Number Agreed	5	Date Agreed	14/07/2021	5	14/07/2021	Recruitment Finished	Yes
20/EE/0204	287569	A PHASE II, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE PHARMACODYNAMIC EFFECTS OF ONCE WEEKLY ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH EARLY (PRODRIMAL TO MILD) ALZHEIMER'S DISEASE	Number Agreed	6	Date Agreed	01/07/2021	11	01/07/2021	Recruitment Finished	Yes
20/SW/0087	1003056	EPITOPE OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM CLINICAL BENEFIT AND SAFETY OF DBV712 IN PEANUT-ALLERGIC CHILDREN (EPOPEX)	Number Agreed	5	Date Agreed	27/11/2021	4	27/11/2021	Recruitment Finished	No
20/YH/0171	284062	An open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301 plus standard of care (SOC) compared to SOC alone in hospitalized participants with COVID-19 WHO grade 3&4 (NOCov2)	Number Agreed	10	Date Agreed	31/07/2021	14	31/07/2021	Recruitment Finished	Yes
20/NW/0230	278525	A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an anti-PD-1 antibody, in Combination with Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants with High-Risk, BCG-Naïve Non-Muscle Invasive Bladder Cancer	Number Agreed	5	Date Agreed	31/10/2021	0	31/10/2021	Recruitment Finished	No

20/EM/0087	274214	An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas.	Number Agreed	2	Date Agreed	31/07/2021	2	27/07/2021	Recruitment Finished	Yes
19/EE/0042	257583	A PHASE III, MULTINATIONAL, MULTICENTER, INVESTIGATOR-MASKED, RANDOMISED, ACTIVE-CONTROLLED TRIAL, COMPARING THE EFFICACY AND SAFETY OF DE-130A WITH XALATANÂ® IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION OVER A 3-MONTH PERIOD, FOLLOWED BY A 12-MONTH FOLLOW-UP WITH OPEN-LABEL DE-130A TREATMENT.	Number Agreed	10	Date Agreed	31/10/2021	0	31/10/2021	Recruitment Finished	No
20/LO/0197	277125	An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies	Number Agreed	5	Date Agreed	29/12/2021	0	29/12/2021	Recruitment Finished	No
19/EE/0379	269900	IPX203-B16-03	Number Agreed	1	Date Agreed	31/12/2021	0	31/03/2021	Recruitment Finished	No
18/EM/0323	251531	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Number Agreed	2	Date Agreed	23/04/2021	0	16/04/2021	Withdrawn By Sponsor	No
20/EE/0031	275993	Multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute noncardioembolic ischemic stroke	Number Agreed	10	Date Agreed	31/08/2021	10	31/08/2021	Recruitment Finished	Yes
18/WS/0218	252602	An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH)	Number Agreed	1	Date Agreed	30/06/2021	0	30/06/2021	Recruitment Finished	No
19/NW/0336	256297	Radiographic imaging Validation and EvALuation for Angio iFR (ReVEAL iFR)	Number Agreed	20	Date Agreed	01/08/2021	9	01/08/2021	Recruitment Finished	No
19/LO/1583	271866	A Phase 2, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Voxelotor in Patients with Sickle Cell Disease	Number Agreed	5	Date Agreed	03/06/2021	2	12/02/2021	Withdrawn By Sponsor	No
19/NE/0312	266862	AN OPEN LABEL PHASE 1A/B STUDY OF MTL-CEBPA IN COMBINATION WITH A PD-1 INHIBITOR (PEMBROLIZUMAB) IN ADULT PATIENTS WITH ADVANCED SOLID TUMOURS (TIMEPOINT)	Number Agreed	5	Date Agreed	31/12/2021	6	31/12/2021	Recruitment Finished	Yes

19/LO/1756	272037	A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma/ CA209-9DW	Number Agreed	2	Date Agreed	01/09/2021	0	01/09/2021	Recruitment Finished	No
17/SC/0605	234167	A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CTX-SPL9111 (a cabazitaxel (CTX)-dendrimer conjugate) in patients with advanced solid tumours	Number Agreed	3	Date Agreed	31/08/2021	13	31/08/2021	Recruitment Finished	Yes
19/SC/0422	268966	An Open-Label, Long-Term Safety Evaluation Study with DCCR	Number Agreed	3	Date Agreed	15/03/2021	1	15/03/2021	Recruitment Finished	No
19/ES/0136	270742	A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy.	Number Agreed	3	Date Agreed	31/12/2021	0	14/05/2021	Recruitment Finished	No
19/NW/0328	263312	A Phase 2 Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis	Number Agreed	2	Date Agreed	31/12/2020	0	15/03/2021	Recruitment Finished	No
19/LO/1153	262506	FORWARD Rigel C-935788-057A: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia	Number Agreed	1	Date Agreed	07/10/2021	0	07/10/2021	Recruitment Finished	No
18/SC/0015	236685	CACZ885T2301	Number Agreed	2	Date Agreed	16/12/2021	0	16/12/2021	Recruitment Finished	No
18/NE/0360	254062	An open-label, non-randomised study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy	Number Agreed	2	Date Agreed	31/03/2021	3	31/03/2021	Recruitment Finished	Yes
19/LO/1152	265415	A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancy harboring activating FGFR mutations and translocations	Number Agreed	3	Date Agreed	30/11/2021	0	15/06/2021	Withdrawn By Sponsor	No
19/WS/0015	257933	A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease	Number Agreed	6	Date Agreed	25/06/2021	1	31/03/2021	Recruitment Finished	No
19/NE/0247	259906	A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat (QGC001) Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction after Acute Myocardial Infarction	Number Agreed	1	Date Agreed	30/06/2021	1	15/04/2021	Recruitment Finished	Yes

19/EE/0168	262098	A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)	Number Agreed	2	Date Agreed	30/09/2021	0	27/08/2021	Recruitment Finished	No
18/SC/0591	250421	A Randomized, Open Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor of High Tumor Mutational Burden (TMB-H)	Number Agreed	3	Date Agreed	21/01/2021	3	15/01/2021	Recruitment Finished	Yes
18/EM/0311	254008	A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Study of PUL-042 Inhalation Solution in Rhinovirus-induced Symptoms in Current Smokers with Gold Stage 0 Chronic Obstructive Pulmonary Disease (COPD)	Number Agreed	20	Date Agreed	01/08/2019	19	21/06/2021	Recruitment Finished	No
19/LO/0699	252712	Tigertriever Revascularization Device Registry	Number Agreed	15	Date Agreed	01/07/2021	5	01/07/2021	Recruitment Finished	No
17/LO/0232	220795	An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson's Disease Complicated by Motor Fluctuations	Number Agreed	4	Date Agreed	17/03/2021	2	17/03/2021	Withdrawn By Sponsor	No
18/SC/0240	230920	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer's Disease	Number Agreed	8	Date Agreed	11/01/2021	9	11/01/2021	Recruitment Finished	Yes
18/NW/0514	249725	SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity	Number Agreed	35	Date Agreed	19/03/2021	35	19/03/2021	Recruitment Finished	Yes
18/LO/0430	241907	An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenia	Number Agreed	1	Date Agreed	01/10/2021	5	01/10/2021	Recruitment Finished	Yes
18/NE/0142	242919	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis	Number Agreed	2	Date Agreed	06/05/2021	2	06/05/2021	Recruitment Finished	Yes
18/SS/0010	238051	A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations	Number Agreed	1	Date Agreed	31/12/2021	1	31/12/2021	Recruitment Finished	Yes

17/LO/1500	224823	A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation Who are candidates for Non-intensive Therapy.	Number Agreed	1	Date Agreed	19/09/2022	0	26/05/2021	Withdrawn By Sponsor	No
17/LO/1320	229845	Single-arm, phase II study of Luspatercept (ACE-536) in anemic patients with MPN-associated myelofibrosis.	Number Agreed	4	Date Agreed	31/12/2021	3	31/12/2021	Recruitment Finished	No
17/WS/0180	225790	A Phase 111b, Randomised, Double-blind, Placebocontrolled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)	Number Agreed	4	Date Agreed	30/04/2021	2	15/01/2021	Recruitment Finished	No
16/EE/0421	209972	A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension	Number Agreed	2	Date Agreed	31/05/2021	0	31/05/2021	Recruitment Finished	No
16/WS/0005	193858	A PHASE 3, LONG-TERM ACTIVE TREATMENT EXTENSION STUDY OF MONGERSEN (GED-0301) IN SUBJECTS WITH CROHN'S DISEASE	Number Agreed	1	Date Agreed	01/11/2021	0	01/11/2021	Recruitment Finished	No